Truist Financial Cuts Globus Medical (NYSE:GMED) Price Target to $100.00

Globus Medical (NYSE:GMED) had its price target cut by Truist Financial from $115.00 to $100.00 in a research report sent to investors on Thursday morning, Marketbeat Ratings reports. They currently have a buy rating on the medical device company’s stock.

Several other research analysts have also issued reports on the stock. Stifel Nicolaus reduced their target price on shares of Globus Medical from $95.00 to $80.00 and set a “hold” rating on the stock in a research note on Wednesday, July 8th. Royal Bank Of Canada reduced their price objective on shares of Globus Medical from $120.00 to $115.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. Needham & Company LLC lifted their target price on shares of Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Piper Sandler dropped their target price on shares of Globus Medical from $115.00 to $100.00 and set an “overweight” rating for the company in a research report on Monday, June 15th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a research note on Monday, July 13th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $103.75.

Globus Medical Price Performance

GMED opened at $77.01 on Thursday. The stock has a market capitalization of $10.45 billion, a P/E ratio of 17.91, a price-to-earnings-growth ratio of 1.59 and a beta of 0.95. The company’s 50 day simple moving average is $79.84 and its 200-day simple moving average is $86.47. Globus Medical has a one year low of $51.79 and a one year high of $101.40.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.20. The firm had revenue of $759.85 million for the quarter, compared to the consensus estimate of $740.35 million. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The business’s revenue for the quarter was up 27.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, analysts anticipate that Globus Medical will post 4.74 EPS for the current year.

Insider Buying and Selling

In other Globus Medical news, Director David D. Davidar sold 25,000 shares of the stock in a transaction on Friday, June 5th. The shares were sold at an average price of $80.76, for a total value of $2,019,000.00. Following the sale, the director directly owned 510,175 shares in the company, valued at approximately $41,201,733. This trade represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 18.38% of the company’s stock.

Institutional Trading of Globus Medical

Hedge funds have recently added to or reduced their stakes in the business. Elevation Wealth Partners LLC grew its stake in Globus Medical by 2,178.6% in the second quarter. Elevation Wealth Partners LLC now owns 319 shares of the medical device company’s stock valued at $25,000 after acquiring an additional 305 shares during the period. Advisory Services Network LLC acquired a new stake in shares of Globus Medical during the third quarter worth about $26,000. EverSource Wealth Advisors LLC raised its position in shares of Globus Medical by 74.3% during the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after purchasing an additional 197 shares during the period. SBI Securities Co. Ltd. lifted its holdings in shares of Globus Medical by 98.2% during the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 167 shares in the last quarter. Finally, Parallel Advisors LLC lifted its holdings in shares of Globus Medical by 45.1% during the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after purchasing an additional 173 shares in the last quarter. Institutional investors and hedge funds own 95.16% of the company’s stock.

Key Globus Medical News

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: GMED’s one-year rally has been attributed to strong growth in both business segments, rising technology adoption, and a debt-free balance sheet, reinforcing confidence in the company’s operating momentum. GMED Stock Surges 43.6% in a Year: What’s Driving the Rally?
• Positive Sentiment: Wall Street still appears constructive on Globus Medical, with Truist reiterating a buy rating even after lowering its price target to $100, which still implies meaningful upside from recent levels. Globus Medical (NYSE:GMED) Price Target Lowered to $100.00 at Truist Financial
• Positive Sentiment: Recent commentary also says GMED still looks undervalued after its recent gains, which may be attracting value-oriented investors. Globus Medical (GMED) Stock Still Looks Undervalued Despite A 39% Return
• Positive Sentiment: Zacks highlighted GMED as a strong value stock, supporting the view that the shares may still have room to run if fundamentals remain solid. Here’s Why Globus Medical (GMED) is a Strong Value Stock
• Neutral Sentiment: The company scheduled its second-quarter 2026 earnings release for August 6, which keeps investors focused on upcoming results and guidance, but does not by itself change the investment thesis. Globus Medical Schedules Second Quarter Earnings Release and Conference Call
• Neutral Sentiment: Globus Medical also announced it will host a conference call to discuss second-quarter results, increasing visibility into the business ahead of earnings. Globus Medical to Announce Second Quarter 2026 Financial Results on August 6
• Negative Sentiment: A shareholder litigation firm said it is investigating possible fiduciary-duty breaches by certain officers and directors, which could create overhang and governance concerns for GMED. Kuehn Law Encourages Investors of Globus Medical, Inc. to Contact Law Firm

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.